Medical Management for BPH: The Role of Combination Therapy Claus Roehrborn, Jeremy P.W. Heaton  European Urology Supplements  Volume 5, Issue 12, Pages 716-721 (August 2006) DOI: 10.1016/j.eursup.2006.06.010 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Effects of doxazosin monotherapy, finasteride monotherapy, combination therapy, and placebo on a composite measure of benign prostatic hyperplasia (BPH) progression, a >4-point rise in the American Urological Association Symptom Index, and the risks of acute urinary retention and invasive therapy for BPH from the Medical Therapy of Prostatic Symptoms study at year 4 [4]. European Urology Supplements 2006 5, 716-721DOI: (10.1016/j.eursup.2006.06.010) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 The impact of baseline prostate volume on the symptomatic benefit of combination therapy versus finasteride or doxazosin monotherapies from the MTOPS study [17]. European Urology Supplements 2006 5, 716-721DOI: (10.1016/j.eursup.2006.06.010) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Risk of retreatment rates with α-blocker therapy by baseline prostate volume (PV) [19]. European Urology Supplements 2006 5, 716-721DOI: (10.1016/j.eursup.2006.06.010) Copyright © 2006 European Association of Urology Terms and Conditions